284 related articles for article (PubMed ID: 16522696)
1. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia.
Ghali JK; Koren MJ; Taylor JR; Brooks-Asplund E; Fan K; Long WA; Smith N
J Clin Endocrinol Metab; 2006 Jun; 91(6):2145-52. PubMed ID: 16522696
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia.
Annane D; Decaux G; Smith N;
Am J Med Sci; 2009 Jan; 337(1):28-36. PubMed ID: 19057376
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia.
Zeltser D; Rosansky S; van Rensburg H; Verbalis JG; Smith N;
Am J Nephrol; 2007; 27(5):447-57. PubMed ID: 17664863
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of 30-minute infusions of conivaptan in euvolemic and hypervolemic hyponatremia.
Koren MJ; Hamad A; Klasen S; Abeyratne A; McNutt BE; Kalra S
Am J Health Syst Pharm; 2011 May; 68(9):818-27. PubMed ID: 21515866
[TBL] [Abstract][Full Text] [Related]
5. Intravenous conivaptan.
Moen MD; Keating GM
Am J Cardiovasc Drugs; 2008; 8(5):341-8; discussion 349. PubMed ID: 18828645
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study.
Verbalis JG; Zeltser D; Smith N; Barve A; Andoh M
Clin Endocrinol (Oxf); 2008 Jul; 69(1):159-68. PubMed ID: 18034777
[TBL] [Abstract][Full Text] [Related]
7. Conivaptan for hyponatremia in the neurocritical care unit.
Wright WL; Asbury WH; Gilmore JL; Samuels OB
Neurocrit Care; 2009; 11(1):6-13. PubMed ID: 19003543
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study.
Mao ZL; Stalker D; Keirns J
Clin Ther; 2009 Jul; 31(7):1542-50. PubMed ID: 19695403
[TBL] [Abstract][Full Text] [Related]
9. Dose comparison of conivaptan (Vaprisol®) in patients with euvolemic or hypervolemic hyponatremia--efficacy, safety, and pharmacokinetics.
Palmer BF; Rock AD; Woodward EJ
Drug Des Devel Ther; 2016; 10():339-51. PubMed ID: 26848258
[TBL] [Abstract][Full Text] [Related]
10. Conivaptan bolus dosing for the correction of hyponatremia in the neurointensive care unit.
Murphy T; Dhar R; Diringer M
Neurocrit Care; 2009; 11(1):14-9. PubMed ID: 19123060
[TBL] [Abstract][Full Text] [Related]
11. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
Schrier RW; Gross P; Gheorghiade M; Berl T; Verbalis JG; Czerwiec FS; Orlandi C;
N Engl J Med; 2006 Nov; 355(20):2099-112. PubMed ID: 17105757
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and Tolerability of Conivaptan and Tolvaptan for the Treatment of Hyponatremia in Neurocritically Ill Patients.
Der-Nigoghossian C; Lesch C; Berger K
Pharmacotherapy; 2017 May; 37(5):528-534. PubMed ID: 28295447
[TBL] [Abstract][Full Text] [Related]
13. Conivaptan: new treatment for hyponatremia.
Walter KA
Am J Health Syst Pharm; 2007 Jul; 64(13):1385-95. PubMed ID: 17592003
[TBL] [Abstract][Full Text] [Related]
14. Use of intravenous conivaptan in neurosurgical patients with hyponatremia from syndrome of inappropriate antidiuretic hormone secretion.
Potts MB; DeGiacomo AF; Deragopian L; Blevins LS
Neurosurgery; 2011 Aug; 69(2):268-73. PubMed ID: 21792136
[TBL] [Abstract][Full Text] [Related]
15. Effect of loading dose and formulation on safety and efficacy of conivaptan in treatment of euvolemic and hypervolemic hyponatremia.
Kalra S; Efrati S; Arthur JM; Oliven A; Velez JC; McNutt BE; Klasen S; Abeyratne A
Am J Health Syst Pharm; 2011 Apr; 68(7):590-8. PubMed ID: 21411800
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of 3% saline vs. conivaptan in achieving hyponatremia treatment goals.
Dominguez M; Perez JA; Patel CB
Methodist Debakey Cardiovasc J; 2013; 9(1):49-53. PubMed ID: 23519387
[TBL] [Abstract][Full Text] [Related]
17. Tolvaptan and Neurocognitive Function in Mild to Moderate Chronic Hyponatremia: A Randomized Trial (INSIGHT).
Verbalis JG; Ellison H; Hobart M; Krasa H; Ouyang J; Czerwiec FS;
Am J Kidney Dis; 2016 Jun; 67(6):893-901. PubMed ID: 26874645
[TBL] [Abstract][Full Text] [Related]
18. A novel vasopressin dual V1A/V2 receptor antagonist, conivaptan hydrochloride, improves hyponatremia in rats with syndrome of inappropriate secretion of antidiuretic hormone (SIADH).
Wada K; Matsukawa U; Fujimori A; Arai Y; Sudoh K; Sasamata M; Miyata K
Biol Pharm Bull; 2007 Jan; 30(1):91-5. PubMed ID: 17202666
[TBL] [Abstract][Full Text] [Related]
19. Open-label randomized trial of the safety and efficacy of a single dose conivaptan to raise serum sodium in patients with traumatic brain injury.
Galton C; Deem S; Yanez ND; Souter M; Chesnut R; Dagal A; Treggiari M
Neurocrit Care; 2011 Jun; 14(3):354-60. PubMed ID: 21409494
[TBL] [Abstract][Full Text] [Related]
20. Observations regarding the use of the aquaretic agent conivaptan for treatment of hyponatremia.
Metzger BL; DeVita MV; Michelis MF
Int Urol Nephrol; 2008; 40(3):725-30. PubMed ID: 18363040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]